Displaying 1 through 8 of 17 Next Page >>
|
| Pantec Biosolutions receives "Honourable Mention" in red dot awards |
| Friday, July 30, 2010 |
Ruggell, Liechtenstein, 30 July 2010- Pantec Biosolutions AG, today announced that its first manufactured product, P.L.E.A.S.E.® Professional’ received an "honourable mention" at the "red dot award: product design 2010" for its particularly successful and innovative design solutions. |
| |
| Pantec Biosolutions Closes CHF 20 Million Financing |
| Tuesday, July 20, 2010 |
Ruggell, Liechtenstein, 20 July 2010- Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the closing of a CHF 20 million investment achieved by two financing rounds. |
| |
| Pantec Biosolutions' P.L.E.A.S.E. Professional® Receives Marketing Authorisation |
| Tuesday, June 1, 2010 |
Ruggell, Liechtenstein, 1 June 2010 - Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced that it has received a CE mark in the EU for the new professional product line of the Company’s transdermal delivery device: P.L.E.A.S.E.® (Painless Laser Epidermal System). |
| |
| Pantec Biosolutions reports successful Phase I for delivery of FSH using P.L.E.A.S.E.® |
| Wednesday, February 24, 2010 |
Ruggell, Liechtenstein, 24 February 2010, Pantec Biosolutions AG announced today that it has achieved excellent results in a Phase I clinical trial of a FSH (follicle stimulating hormone) patch used in conjunction with the company’s novel P.L.E.A.S.E.® (Painless Laser Epidermal System) technology. Although smaller peptides and some proteins have previously been delivered transdermally, this is the first time a protein as large as 32 KDa has been successfully delivered in this way. |
| |
| Pantec Biosolutions is Granted SME Status in EU |
| Tuesday, December 15, 2009 |
Ruggell, Liechtenstein, 15 December 2009 - Pantec Biosolutions AG, announced today that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted SME (Small and Medium Sized Enterprise) status to Pantec Biosolutions. |
| |
| Pantec Biosolutions Granted European Patent for P.L.E.A.S.E.® |
| Thursday, September 24, 2009 |
Ruggell, Liechtenstein, 24 September 2009 - Pantec Biosolutions AG, a privately-owned company developing innovative transdermal drug delivery products, announced today that it has been granted European Patent No. EP1874213, entitled 'LASER MICROPORATOR' by the European Patent Office. |
| |
| Pantec Biosolutions reports successful Phase I study into the delivery of triptorelin using P.L.E.A.S.E.® technology |
| Monday, April 20, 2009 |
| Ruggell, Liechtenstein, 20 April 2009, Pantec Biosolutions AG, a privately-owned company developing innovative transdermal drug delivery products, announced today that it has achieved excellent results in a Phase I clinical trial of a triptorelin patch used in conjunction with the company’s novel P.L.E.A.S.E.® (Painless Laser Epidermal System) |
| |
| Pantec Biosolutions Expands Scientific Advisory Board |
| Tuesday, February 17, 2009 |
| Ruggell, Liechtenstein, 17 February 2009, Pantec Biosolutions AG, a privately-owned company developing innovative technologies for transdermal drug delivery, today announced the expansion of its Scientific Advisory Board
|
| |
Next Page >>
|